Core Insights - The company reported total revenue of $127.6 million for Q4 2025 and $460.2 million for the entire year of 2025 [1] - Product revenue for Q4 2025 was $127.1 million, up 17% from $108.5 million in Q4 2024, with a constant exchange rate (CER) growth of 16% [1] - For the full year 2025, product revenue was $457.2 million, a 15% increase from $397.6 million in 2024, with a CER growth of 16% [1] - The growth in product revenue was primarily driven by increased sales of Dingyoule and Niuzainuo [1] Financial Performance - The net loss for Q4 2025 was $50.4 million, compared to a net loss of $81.7 million in Q4 2024 [1] - The total net loss for the year 2025 was $175.5 million, down from a net loss of $257.1 million in 2024 [1] - The reduction in net loss was mainly due to faster growth in product revenue compared to operating expenses and a shift from foreign exchange losses to gains, although offset by a decrease in interest income [1]
再鼎医药(09688.HK)2025年第四季度亏损净额为5040万美元 2025年全年亏损净额为1.755亿美元